Selected article for: "acute respiratory syndrome and mabs development"
Author: Jin, Yujia; Lei, Cheng; Hu, Dan; Dimitrov, Dimiter S.; Ying, Tianlei
Title: Human monoclonal antibodies as candidate therapeutics against emerging viruses
  • Cord-id: n0uzbda0
  • Document date: 2017_11_20
    • ID: n0uzbda0
    Snippet: The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, includ
    Document: The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.

    Search related documents:
    Co phrase search for related documents
    • abundant protein and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • abundant protein and low concentration: 1
    • abundant protein and low production cost: 1
    • active vaccination and acute respiratory syndrome: 1, 2, 3
    • active vaccination and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
    • active vaccination and low immunogenicity: 1, 2
    • active vaccination and low production cost: 1
    • acute respiratory syndrome and additional sars outbreak: 1, 2
    • acute respiratory syndrome and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low cost method: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and low immunogenicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory syndrome and low production cost: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and mab production: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and low cost method: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and low immunogenicity: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute sars cov respiratory syndrome coronavirus and low production cost: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and mab production: 1